An NCI-designated Comprehensive Cancer Center
The Analytical Pharmacology Core Facility (APCF) encourages and facilitates collaborative research between basic scientists and clinicians by providing extensive pharmacology expertise and a wide range of analytical services. To this end, the APCF conducts pharmacokinetic and pharmacodynamic studies for both clinical trials and peer-reviewed preclinical studies. The facility and its services are available to both City of Hope and non-City of Hope researchers, and it has been supported by City of Hope’s NCI-funded Cancer Center Support Grant since its establishment in 1994.
 
Key instrumentation includes 4 triple quadrupole mass spectrometers, including a Micromass Quattro Ultima, a Waters Quattro Premier XE, an AB Sciex QTRAP 5500, and a Waters Xevo-TQXS. All systems provide state-of-the-art selectivity and sensitivity for detecting and quantifying analytes in complex biological matrices and are interfaced with a range of HPLC front-end components. Additional key core equipment includes an Agilent 8800 inductively-coupled plasma triple quadrupole mass spectrometer (ICP-MS) for quantitation of metals and metal-containing compounds. For analysis of biological agents, the Core has two FLEXMAP 3D Bioplex instruments for multiplex immunoassays, an Isolight benchtop single cell cytokine analyzer, a Bio-Rad QX200 Droplet Digital PCR, two Bio-Rad CFX96 QPCR instruments, a FLUOstar OPTIMA multi-label plate reader, a Miltenyi Biotech MACSQuant Analyzer 10 flow cytometer, and a Guava PCA-96 analytical cell analyzer.

Meet the Team

Core Director, Analytical Pharmacology
Manager, Immunochemistry Services
Manager, Analytical Chemistry

Abstract for Grants

The APCF encourages and facilitates collaborative research between basic scientists and clinicians by providing extensive pharmacology expertise and a wide range of analytical services. To this end, the APCF conducts pharmacokinetic and pharmacodynamic studies for both clinical trial correlative studies and peer-reviewed preclinical studies.
 
Core services include;
 
  1. initial consultation on research projects,
  2. study design and protocol review,
  3. development, implementation, and validation of analytical methods,
  4. sample acquisition, processing, tracking, and storage,
  5. sample analysis (LC-MS/MS, ICP-QQQ, AAS, GC/MS, HPLC, qPCR, Luminex, and ELISA),
  6. pharmacokinetic programming and data analysis, and
  7. participation in collaborative writing.
     
The APCF currently occupies 2500 sq. ft. of space in the Shapiro building. The space includes a 275 square foot tissue culture area, a 275 square foot area dedicated to qPCR and ELISA, and a 250 square foot room dedicated to liquid nitrogen, -80°, and -20° C storage and a 200 square foot room housing dedicated to Luminex equipment. Additional freezers for long-term sample storage are located in the Beckman Center Freezer Farm. Laboratory operations are guided by GLP principles of operation, with all requisite equipment being 21 CFR part 11 compliant. APCF includes state-of-the-art equipment for monitoring immune responses to cancer therapy and have been processing serum and PBMC’s for preclinical and clinical investigators for more than 10 years. APCF has performed over 500 Luminex assays and are a part of the NIH-NIAID-DAIDS external quality assurance program oversight laboratory program. At the time of the last performance review, APCF received 98.9 points (out of 100) for Luminex EP4, which corresponds to a performance rating of “Excellent”, the highest rating possible.

Publications

Default publication image
Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting
Default publication image
Quantitative Evaluation of Intraventricular Delivery of Therapeutic Neural Stem Cells to Orthotopic Glioma
Default publication image
8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia
Default publication image
A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction
Default publication image
A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity
Default publication image
A Phase I Trial of Topotecan plus Tivantinib in Patients with Advanced Solid Tumors
Default publication image
The anti-cancer activity of a first-in-class small molecule targeting PCNA